Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.59 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355363 | 0.88 | ALDH1A1 (0.60) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL30643073 | 0.88 | POLB (0.62) | POLBALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL379054 | 0.81 | ALDH1A1 (0.67) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL11636578 | 0.81 | ALDH1A1 (0.58) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL5563599 | 0.80 | KDM4E (0.61) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL18144902 | 0.79 | ALDH1A1 (0.69) | ALDH1A1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2976354 | 0.79 | AKR1B1 (0.76) | ALDH1A1KDM4ECSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4256569 | 0.79 | ALDH1A1 (0.69) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL9613247 | 0.79 | LMNA (0.69) | POLBALDH1A1KDM4ECSNK2A2CSNK2B | |
| SCHEMBL13855906 | 0.78 | ALDH1A1 (0.63) | POLBALDH1A1KDM4ECSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-109641864-B | Anti-infective agents | 邓迪大学 | 2023-04-04 | — | — | CN | disclosed |
| US-11485720-B2 | Anti-infective agents | UNIVERSITY OF DUNDEE (GB) | 2022-11-01 | — | — | US | disclosed |
| EP-3472141-B1 | ANTI-INFECTIVE AGENTS | UNIV DUNDEE (GB) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2021-04-08 | — | — | US | disclosed |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2019-07-25 | — | — | US | disclosed |
| EP-3472141-A1 | ANTI-INFECTIVE AGENTS | University Of Dundee (GB) | 2019-04-24 | — | — | EP | disclosed |
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-12-07 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1606281-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083199-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276485-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | POLB 2972/4885ALDH1A1 2415/4885KDM4E 165/4885 |
| US-11485720-B2 | Anti-infective agents | C1R, RRS1, ARG1 | POLB 1211/4885ALDH1A1 3749/4885KDM4E 2159/4885 |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | POLB 653/4885ALDH1A1 102/4885KDM4E 2232/4885 |
| US-20210101877-A1 | ANTI-INFECTIVE AGENTS | C1R, RRS1, ARG1 | POLB 1211/4885ALDH1A1 3749/4885KDM4E 2159/4885 |
| US-20190225592-A1 | ANTI-INFECTIVE AGENTS | C1R, ARG1, MSR1 | POLB 1062/4885ALDH1A1 3685/4885KDM4E 2344/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | POLB 2972/4885ALDH1A1 2415/4885KDM4E 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.